Ординатура / Офтальмология / Английские материалы / Ocular Disease Mechanisms and Management_Levin, Albert_2010

5.Chadha V, Borooah S, Tey A, et al. Floppy iris behaviour during cataract surgery: associations and variations. Br J Ophthalmol 2007;91:40–42.

6.Chang DF, Osher RH, Wang L, et al. Prospective multicenter evaluation of cataract surgery in patients taking tamsulosin (flomax). Ophthalmology 2007;114:957–964.

7.Cheung CMG, Awan MAR, Sandramouli S. Prevalence and clinical findings of tamsulosin-associated intraoperative floppy-iris syndrome. J Cataract Refract Surg 2006;32:1336–1339.

8.Manivikar S, Allen D. Cataract surgery management in patients taking

tamsulosin: staged approach. J Cataract Refract Surg 2006;32:1611–1614.

9.Takmaz T, Can I. Intraoperative floppyiris syndrome: do we know everything about it? J Cataract Refract Surg 2007;33:1110–1112.

10.Pringle E, Packard R. Antipsychotic agent as an etiologic agent for IFIS. J Cataract Refract Surg 2005;31:2240– 2241.

11.Oetting TA, Omphroy LC. Modified technique using flexible iris retractors in clear corneal surgery. J Cataract Refract Surg 2002;28:596–598.

12.Arshinoff SA. Using BSS with viscoadaptives in the ultimate soft-shell

Key references

technique. J Cataract Refract Surg 2002;28:1509–1514.

13.Bendel RE, Phillips MB. Preoperative use of atropine to prevent intraoperative floppy-iris syndrome in patients taking tamsulosin. J Cataract Refract Surg 2006;32:1603–1605.

14.Shugar JK. Use of epinephrine for IFIS prophylaxis. J Cataract Refract Surg 2006;32:1074–1075.

15.Masket S, Belani S. Combined preoperative atropine sulfate 1% and intracameral nonpreserved epinephrine hydrochloride 1 : 2500 for management of intraoperative floppy-iris syndrome.

J Cataract Refract Surg 2007;33:580–582.

S E C T I O N 5

Neuro-ophthalmology

C H A P T E R 37

Optic neuritis

Clinical background

Optic neuritis is an inflammatory disorder of autoimmune optic nerve demyelination. It is often the first clinical sign of multiple sclerosis (MS).1,2 Optic neuritis is second only to glaucoma as the most common optic neuropathy in the USA. There are approximately 25 000 cases diagnosed per year. Optic neuritis patients are young, typically more than 10 years of age but less than 50 years of age. The clinical symptomatology is characterized by sudden painful visual loss in one eye, although occasionally both eyes can be simultaneously involved. The pain is usually exacerbated by eye movement. Optic neuritis associated with transverse myelitis may be due to Devics disease.

Clinical examination of patients with acute optic neuritis usually reveals a relative afferent pupillary defect (unilateral cases or bilateral cases with asymmetric involvement), visual field deficits, loss of visual acuity, contrast sensitivity, color vision, and stereopsis. The intraocular segment of optic nerve known as the optic nerve head that is visible by clinical examination with an ophthalmoscope is normal in threequarters of cases. When swelling of the optic nerve head is present, leakage of lipid from the vasculature of the swollen disc into the neurosensory retina sometimes results in a macular star pattern. Although this is coined neuroretinitis, retinal inflammation is typically absent.

In a landmark study of almost 500 optic neuritis patients, the Optic Neuritis Treatment Trial (ONTT), visual field defects were nonspecific in approximately half the patients.1 In those patients with defects considered specific for an optic neuropathy, one-third were altitudinal defects previously associated with another disorder, ischemic optic neuropathy, caused by infarction of the optic nerve head that also has swelling of the optic nerve head. Occasionally the visual field defects of optic neuritis may be a bitemporal hemianopsia or junctional scotoma mimicking a pituitary adenoma or other suprasellar mass such as an aneurysm compressing the optic chiasm. Such cases may be resolved by neuroimaging with magnetic resonance imaging (MRI) or computed tomography (CT), as done for two patients inadvertently entered into the ONTT who turned out to have a pituitary adenoma or aneurysm as the cause of their optic neuropathy. MRI is the imaging modality of choice, as it typically

reveals contrast enhancement of the optic nerve characteristic of disruption of the blood–optic nerve barrier in most cases of acute optic neuritis.2 For visualization of contrast enhancement of the intraorbital optic nerve, a fat suppression pulse sequence is necessary. MRI also reveals asymptomatic lesions of the intracranial white matter associated with the MS and excludes compressive lesions.

Etiology

While optic neuritis may occur in isolation or in association with MS, systemic diseases such as sarcoidosis,3,4 collagen vascular disease,5 or the remote effects of cancer6 and infections including cat scratch,7,8 human immunodeficiency virus (HIV),9,10 syphilis,11 retinal necrosis,12,13 Whipple’s disease,14 or West Nile encephalitis15 may be masqueraders of optic neuritis. They can be elucidated by atypical features such as persistence of pain, progression of visual loss beyond 2 weeks, or lack of visual recovery after 4 weeks.

Genetics

Traditionally, optic neuritis and MS have not been considered to be genetic disorders, apart from association with certain human leukocyte antigen (HLA) haplotypes. Recently, single nucleotide polymorphisms have been detected in the mitochondrial genome of some optic neuritis patients16 and in the gene encoding the interleukin-7 receptor alpha chain (IL7R) in MS patients (Box 37.1).17,18

Prognosis

The prognosis of visual loss in optic neuritis is typically good.19 Visual loss stops worsening 2 weeks after it begins and by 4 weeks most patients show signs of recovery.20 Recovery of vision occurs in almost all patients after their initial bout of optic neuritis.21 Still, 6% are left with 20/50 or worse, and 3% are devastated by 20/200 or worse, i.e., legal blindness. Even though visual acuity recovers to 20/20 in 70% of patients and even more (87%) recover to 20/25, most of these patients show signs of residual deficits in their contrast sensitivity, visual fields, and stereopsis 10 years later, thereby suggesting these troubling deficits are permanent. A single recurrence of optic neuritis is common (60%

Box 37.1 

•Optic neuritis is an inflammatory disorder of autoimmune optic nerve demyelination that is often the first clinical sign of multiple sclerosis

•Optic neuritis is second only to glaucoma as the commonest optic neuropathy in the USA

•Traditionally, optic neuritis and multiple sclerosis have not been considered to be genetic disorders. Recently, single nucleotide polymorphisms have been detected in the mitochondrial genome of some optic neuritis patients and in the gene encoding the interleukin-7 receptor alpha chain (IL7R) in multiple sclerosis patients

Pathophysiology

Box 37.3 

•The experimental autoimmune encephalomyelitis (EAE) animal model has impacted the design and direction of both basic and clinical research to understand the pathogenesis and treatment of multiple sclerosis

•The magnetic resonance imaging and reactive oxygen species histopathologic similarities of the EAE animal model to human optic neuritis suggest that EAE is the ideal model system to investigate and target the underlying mechanisms by which retinal ganglion cells and their axons are lost in optic neuritis and multiple sclerosis

Box 37.2 

•The traditional view of optic neuritis and multiple sclerosis has emphasized demyelination as the primary event in the disease process

•The targeted cells appear to be the oligodendrocytes that are responsible for producing the axon’s myelin. In fact, apoptosis of oligodendrocytes has been described as the earliest event in the early lesions of multiple sclerosis

•Recently this focus has changed. Axonal and neuronal loss are increasingly recognized as the primary factors contributing to persistent deficits and disability in multiple sclerosis and optic neuritis

within 10 years), as are multiple recurrences. Repeated attacks can lead to more severe visual loss, and in some patients legal blindness.22–30

Pathophysiology

The traditional view of optic neuritis and MS emphasizes demyelination as the primary event in the disease process. The targeted cells appear to be the oligodendrocytes that are responsible for producing the axon’s myelin (Box 37.2). In fact, apoptosis of oligodendrocytes has been described as the earliest event in the early lesions of MS.31 Recently this focus has changed. Axonal and neuronal loss are increasingly recognized as the primary factors contributing to persistent deficits and disability in MS and optic neuritis,22,32,33 as also revealed by optical coherence tomography (OCT).24,25 Permanent disability is believed to develop when a threshold of neuronal and axonal loss is reached and compensatory responses are exhausted. There is relatively little known about the underlying molecular mechanisms involved in the neurodegeneration process and as a consequence there is no treatment for this phase of the disease. A leading hypothesis is that axons are transected by inflammatory cells (ICs).34,35 However, this does not explain the degeneration of neurons seen well before the IC infiltration or the progressive loss of function after the inflammatory phase has subsided.36 Mitochondria play a key role in the pathogenesis of many neurological diseases,37 but the role of the organelle has only recently been recognized in optic neuritis and MS.38,39

Animal model

The experimental autoimmune encephalomyelitis (EAE) animal model has impacted the design and direction of both basic and clinical research to understand the pathogenesis and treatment of MS.40,41 Immunomodulatory cyclophosphamide, ciclosporin A, copolymer 1, antibodies to specific lymphocyte subsets, and immunization with T-cell receptor peptides initially evaluated in EAE have been or are being applied to MS.42 The EAE model has an additional important advantage over other animal models. The alterations in the permeability of the blood–brain barrier (BBB) play a major role in the pathogenesis of EAE-induced demyelination.43 Comparable disruption of this barrier occurs in immunemediated disorders such as optic neuritis and MS. In fact, optic neuritis and MS are believed to be disorders of the BBB through which ICs and humoral factors producing demyelination gain access to the central nervous system (CNS). Histopathology of inactive EAE lesions shows foci of gliosis without active inflammation that are also seen in MS. Active optic nerve lesions in EAE reveal demyelination, mononuclear cell infiltration, and phagocytosis of axons and myelin by effector macrophages.44 These findings are also seen in MS. In EAE there is also an immunogenetically restricted recognition system that involves the major histocompati­ bility antigens. Helper CD4 lymphocytes first adhere to endothelial cells, and then they infiltrate the CNS. The inflammatory response is amplified by recruitment of ICs and release of mediators, such as cytokines, antibodies, and reactive oxygen species (ROS). It is presumed that similar mechanisms may contribute to the pathogenesis of MS, but this is not known because in most patients the disease is already well established at clinical presentation.45

Histopathologic findings of a patient with optic neuritis exhibited inflammation and demyelination that is also seen in the EAE optic nerve.46 Since human pathologic material is generally unavailable, MRI has provided an important link of EAE to optic neuritis and MS. MRIs of the optic nerve showing contrast enhancement and demyelination are similar in EAE and human disease.47,48 The MRI, histopathologic, and ROS similarities of the EAE animal model to human optic neuritis suggest that EAE is the ideal model system to investigate and target the underlying mechanisms by which retinal ganglion cells and their axons are lost in optic neuritis and MS (Box 37.3).

Section 5  Neuro-ophthalmology Chapter 37  Optic neuritis

Neurodegeneration in EAE

Axonal loss is seen in acute EAE.49 Loss of retinal ganglion cells (RGCs) is also common to chronic EAE50,51 as well as to relapsing/remitting EAE.52 The incidence of optic neuritis is very high in both model systems with one significant difference. In chronic EAE, RGC loss occurs prior to the infiltration of ICs,36 but not in relapsing and remitting EAE52 or in myelin oligodendrocyte glycoprotein (MOG)-specific T-cell receptor transgenic mice that develop isolated optic neuritis, usually without any other characteristic lesions of EAE in the brain or in the spinal cord.53 Mitochondrial dysfunction may play an important role in the neurodegeneration of EAE and MS and this process begins much sooner than currently believed.54,55 Mitochondria are the primary source of cellular adenosine triphosphate (ATP), energizing neurons and axons in the CNS. Current evidence implicating mitochondria is a loss of ATPase activity in MS lesions,39 but how? In addition, mitochondria are the primary source of cellular ROS. Increased ROS activity is linked to many neurodegenerative diseases that have as a major feature axonal and neuronal loss.38 Still, while ROS have been recognized among the mediators of CNS injury in EAE and MS,56–64 the contribution of mitochondria to ROS activity and cell death has received little attention. The rest of this chapter reviews the role of mitochondrial respiration, oxidative stress, and the potential effects of modulating antioxidant gene expression in the visual system of mice induced with EAE, with a focus on long-term suppression of neurodegeneration.

Mitochondrial injury in EAE starts early

ICs that cause the classical demyelination of EAE and MS are believed to be the primary source of oxidative stress.22 IC infiltration typically begins within 1–2 weeks of antigenic sensitization for EAE. Qi and coworkers54 focused on the role of the mitochondrion as a potential source of ROS and target of oxidative injury before this initial phase of disease. Mitochondria were isolated from the retina, optic nerve, brain, and spinal cord of animals 3 and 6 days after sensitization for EAE, then probed for ROS. At this early stage none of the animals exhibited any clinical signs of EAE. As an initial gauge of ROS activity they used the peroxynitrite-mediated nitration of tyrosine residues that was detected with an antibody directed against nitrotyrosine. Peroxynitrite formed by the reaction of two other ROS, superoxide and nitric oxide, has been implicated in the pathogenesis of EAE, optic neuritis, and MS.65–67 They found nitration of mitochondrial proteins in the EAE nervous system began as early as 3 days after sensitization for EAE (Figure 37.1).54 Control specimens of unsensitized animals did exhibit some mitochondrial protein nitration indicative of the basal ROS activity that occurs under normal physiologic conditions. Peroxynitrite can inactivate proteins,68–72 but which ones?

Respiratory chain, glycolytic, and chaperone proteins are altered

Using a proteonomics approach, Qi and coworkers54 identified the nitrated mitochondrial proteins. In situ trypsin

280

Figure 37.1  Immunoblots of mitochondria isolated from the optic nerve, brain, and spinal cord revealed peroxynitrite-mediated nitration of tyrosine residues at day 3 and day 6 after sensitization for experimental autoimmune encephalomyelitis, but not in the control specimens (day 0). (Reproduced with permission from Qi X, Lewin AS, Sun L, et al. Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J Biol Chem 2006;20:31950–31962.)

digests of the excised protein bands were submitted for mass spectroscopy.73 When the peptide fingerprints obtained were submitted for protein database sequence analysis the highest match was for mitochondrial heat shock protein 70 (mtHsp70) (Figure 37.2A). This chaperone is critical not only to the import of nuclear-encoded mitochondrial proteins from the cytosol, but also protein folding and assembly into the mitochondrial matrix. In vitro, loss of mtHsp70 function results in aggregation of mitochondria and profoundly alters the morphology of the organelle.74 Qi and coworkers54 showed these very same ultrastructural changes in the mitochondria of EAE axons.

Protein database sequence analysis of the other peptide fingerprints obtained (Figure 37.2B) included two respiratory chain complexes. They were identified as the NADPHubiquinone oxidoreductase B14 subunit (NDUFA6) of complex I and cytochrome c oxidase subunit IV. Loss of activity of complexes I and IV induced by ROS here potentially contributes to loss of cellular energy.75,76 NDUFA6 is critical to the assembly of the holo complex I. Protein database sequence analysis of other peptide fingerprints obtained included the calcium-transporting ATPase and the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Alterations in calcium sequestration, another important function of mitochondria, contribute to loss of mitochondrial membrane potential that can lead to cell death.77,78 In addition to its role in glycolysis, translocation of nitrosylated GAPDH to the nucleus is linked to apoptotic cell death, or necrosis with ATP depletion.79 Both mechanisms may induce loss of retinal ganglion cells in EAE.

ROS suppress oxidative phosphorylation

Exposure of RGCs to peroxynitrite for 24 hours suppressed the rate of ATP synthesis by 94%, relative to RGCs grown in normal culture media (Figure 37.3). This degree of impairment in oxidative phosphorylation is much greater than that seen in fatal neurodegenerative diseases caused by mutated mitochondrial DNA such as maternally inherited Leigh’s syndrome and neuropathy ataxia retinitis pigmentosa or the blinding disease Leber hereditary optic neuropathy that

SEQUEST search: IINEPTAAAIAYGLDK from 70 kD heat shock protein, Xcorr = 4.17

MS/MS spectrum of m/z 831.7

primarily results in loss of RGCs.80,81 Thus, loss of ATP synthesis induced by ROS can potentially have a severe impact on optic nerve function and cell survival in EAE and perhaps MS.

Antioxidant gene therapy suppresses loss of OXPHOS in vitro

Cellular defenses against ROS are present to some degree in all tissues and organs. They include the antioxidant enzymes superoxide dismutase (SOD), catalase, and glutathione per-

oxidase. Unfortunately, there are no endogenous defenses per se against peroxynitrite. However, defense against a key reactant, superoxide, leading to peroxynitrite formation does exist in all cells. SOD dismutes superoxide to hydrogen peroxide (H2O2) that can be further metabolized by the actions of catalase and glutathione peroxidase to water and molecular oxygen. Several isoforms of SOD exist. The manganese SOD (MnSOD), encoded by the SOD2 gene, is exclusively mitochondrial. The copper/zinc (Cu/Zn) SOD, encoded by the SOD1 gene, is primarily cytoplasmic, but it is also found in the mitochondrial and nuclear compartments.82,83

Figure 37.3  A histogram of adenosine triphosphate (ATP) synthesis shows that, relative to retinal ganglion cells (RGC-5) grown in normal culture medium (striped bar), RGC-5 cells incubated with 250 M of peroxynitrite added to the medium and transfected with AAV-GFP (white bar) had depressed mitochondrial ATP synthesis. RGC-5 cells transfected with AAV-SOD2 had partial rescue of ATP synthesis (black bar).

ROS localization in EAE

In the EAE optic nerve the distribution of inflammation and peroxynitrite-mediated protein nitration is remarkably similar to findings in a human optic neuritis specimen.67 ROS have been linked to loss of mitochondrial membrane potential.54 This can initiate a cascade of events leading to death of retinal ganglion cells, whose axons comprise the optic nerve.84 Qi and coworkers85 looked at mitochondrial membrane potential (Figure 37.4A) in the optic nerve 6 days after antigenic sensitization for EAE. Hydrogen peroxide labeled green by dichorofluordiacetate (Figure 37.4B) had a heavy presence at perineural and perivascular foci with the mitochondrial membrane potential sensing dye MitoTracker red. However, at several perivascular foci where hydrogen peroxide was highly expressed, mitochondrial membrane potential was diminished or even completely lost (Figure 37.4C). It was also found that loss of mitochondrial membrane potential detected by MitoTracker green was associated with superoxide labeled red by dihydroethedium. Thus, in vivo mitochondrial function is altered by ROS activity.

swollen with dissolution of cristae. These mitochondrial findings were not limited to fibers with loss of the myelin sheath, considered the hallmark of MS and EAE.86,87 They were more widespread. Myelinated axons also contained swollen mitochondria that exhibited disorganization and dissolution of cristae, some to the point that only a double membranous bag identified the organelle.

To determine the pathogenicity of mitochondrial ROS activity in EAE, Qi and coworkers85 suppressed antioxidant defenses in the organelle by using a ribozyme designed to target the SOD2 mRNA for destruction. This ribozyme, delivered by the adenoassociate virus (AAV) vector, substantially reduced mitochondrial SOD activity, exacerbating mitochondrial and axonal edema and resulting in massive optic nerve head swelling (Figure 37.5C), RGC loss (Figure 37.5G), and myelin fiber loss. These findings, seen a month after EAE sensitization and intraocular injection of the AAV constructs, illustrate the detrimental role that increased mitochondrial ROS activity may play in acute EAE.

To protect the optic nerves against EAE, Qi and coworkers85 augmented anti-ROS defenses. They found that AAV- SOD2-inoculated nerves exhibited less mitochondrial and axonal and disc swelling (Figure 37.5D), with 46% more myelin fiber preservation than the contralateral nerves inoculated with AAV-GFP. RGCs were also preserved (Figure 37.5H). The suppression of mitochondrial injury by SOD2 was not limited to demyelinated axons. It was seen in myelinated axons, with less hydropic degeneration, disorganization, and dissolution of cristae.

Comparisons to the normal optic nerve further emphasized the importance of these findings. Relative to the normal optic nerve, acute EAE eyes lost two-thirds of their optic nerve myelin fiber area. Treatment with AAV-SOD2 mitigated this by half, to a 50% loss relative to normal optic nerves. Thus, the protective effect achieved here approached the threshold beyond which visual loss is believed to be clinically symptomatic.88 Therefore, SOD2 treatment may potentially prevent irreversible visual loss, by reducing the threshold of myelin fiber injury in the optic nerve. Still, proof of a long-term protective effect is necessary for SOD2, a lesson learned from the opposing effects of nitric oxide in suppressing acute EAE, but aggravating remissions during chronic stages of the disease.39

Modulation of anti-ROS genes alters acute optic neuritis

Qi and coworkers85 examined the effect of antioxidant gene therapy in experimental optic neuritis. They found that, relative to the normal optic nerve (Figure 37.5A), a month after sensitization for EAE, filling of the optic cup and displacement of the peripapillary retina are seen in EAE (Figure 37.5B). This is illustrative of the histologic features of optic disc edema, also visible by ophthalmoscopy of optic neuritis patients. This finding was due predominantly to hydropic degeneration of axons. Relative to the normal retina (Figure 37.5E), loss of RGCs was not yet apparent (Figure 37.5F). Indicative of mitochondrial ROS activity, electron-dense cerium perhydroxide reaction product was found formed by the reaction of perfused cerium chloride and endogenous hydrogen peroxide within mitochondria (Figure 37.6), some

282

Long-term antioxidant gene therapy suppresses optic neuritis

Optic nerve degeneration associated with optic neuritis and MS may develop after just a single attack.89 Typically, irreversible visual loss develops after several recurrences.90 MRI is increasingly being relied on as the tool to test the effectiveness of treatments designed to suppress MS. Qi and coworkers85 used volume measurements of the optic nerve obtained by serial three-dimensional MRIs to follow the changes associated with EAE (Figure 37.7). MRIs of these animals were performed at 2 weeks, then 1, 3, 4, 6, 7, and 12 months following sensitization for EAE. The right eyes received intraocular injections of AAV-SOD2. The left eyes were injected with AAV-GFP. Since ocular injections may be associated with the release of growth factors that can sometimes offer a protective effect, another group of animals that received no ocular

Figure 37.6  Transmission electron microscopy shows that cerium perhydroxide reaction product (arrows), formed by the reaction of endogenous hydrogen peroxide with perfused cerium chloride, is evident within mitochondria, some swollen with dissolution of cristae in the 1-month experimental autoimmune encephalomyelitis optic nerve. (Reproduced with permission from Qi X, Lewin AS, Sun L, et al. Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 2007;48:681–691.)

viral inoculation were sensitized for EAE. Optic nerve volumes between the right and left eyes of this group were the same throughout the course of EAE studied. Though disease activity is often variable between animals with EAE, as is often the case with MS patients, the severity of disease did not substantially vary between eyes of the same animal.

During the acute stages, 2 and 4 weeks after EAE sensitization, optic nerve volumes for the GFP-inoculated nerves increased relative to SOD2 treatment, thus reflecting an

initial decrease in swelling with SOD2 treatment. Later, by the third month and beyond, Qi and coworkers85 detected a loss of optic nerve volume. This optic nerve degeneration was suppressed by SOD2 gene inoculation as long as 1 year after sensitization for EAE, the longest interval studied. Postmortem examinations confirmed the long-term protective effect of SOD2. Excised optic nerves clearly show that, relative to GFP inoculation, the characteristic optic atrophy was suppressed by SOD2 gene inoculation. The effects of EAE were evident in the optic nerve, where myelin fiber area was reduced by 49% relative to normal animals, after 1 year. With SOD2, myelin fiber area diminished, but only by 23%. Thus, treatment offered a twofold protective effect when compared to the normal optic nerve. Relative to the EAE optic nerve, SOD2 nerves had 51% more myelin fiber preservation, somewhat less when measured against the GFP- inoculated eyes (31%). Excavation of the optic nerve head, atrophy of the retrobulbar nerve (Figure 37.8A and 37.8C), and myelin fiber loss (Figure 37.9A) were suppressed with SOD2 (Figures 37.8B and 37.8D). Degenerating axons, some with aggregation of mitochondria, hydropic degeneration, and loss of cristae, evidenced the ongoing neurodegeneration not only at 3 months, but also at 1 year after sensitization for EAE.

Antioxidant gene therapy suppresses neuronal degeneration

The protective effect of SOD2 seen in the optic nerve was mirrored in the retina, where the RGC soma is located. Unlike their findings in acute EAE, where degeneration of the nerve fiber layer and loss of retinal ganglion cells was mainly evident in anti-SOD2 ribozyme-inoculated eyes,84 RGC loss predominated in the chronic stages of EAE. SOD2 treatment preserved the nerve fiber layer and RGCs. Quantitative analysis revealed a 32% loss of retinal ganglion cells a year after sensitization for EAE, relative to normal animals (Figure 37.9B). Qi and coworkers85 found that SOD2 sup-

pressed ganglion cell loss fourfold, limiting it to just 7% in EAE. Even at 1 year, retinal ganglion cells of unprotected and GFP-inoculated EAE animals were still undergoing apoptosis. This suggested that the neurodegenerative process was ongoing and still active even this late in the disease course, and emphasized the potential value of SOD2 gene therapy to suppress it in EAE and perhaps patients with optic neuritis and MS.

Additional approaches to suppress axonal loss

Using a different approach for neuroprotection, Shindler and coworkers91 found that intravitreal injections of the SIRT1 activator, resveratrol, suppressed RGC loss in SJL/J mice sensitized for EAE. Targeting mitochondria, Forte and coworkers78 showed that transgenic mice with knockout of the gene encoding cyclophilin D that were sensitized for EAE had suppression of axonal loss in the spinal cord. Cyclophi-

286

Box 37.4  Strategies for neuroprotection tested in

experimental autoimmune encephalomyelitis (EAE)

•Mitochondrial antioxidant gene therapy with SOD2 suppressed retinal ganglion cell loss fourfold, limiting it to just 7% even

1 year after induction of EAE

•SIRT1 activator, resveratrol, suppressed RGC loss 1 month after sensitization for EAE

•Knockout of the gene encoding cyclophilin D that regulates the mitochondrial permeability transition pore and calcium sequestration suppressed axonal loss in the spinal cord

lin D regulates the mitochondrial permeability transition pore and calcium sequestration. Although they did not focus their studies on the retina or optic nerve, neurons isolated from transgenic knockout mice were resistant to oxidative stress and mitochondria lacking cyclophilin D had increased levels of sequestered calcium (Box 37.4).